



Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild

COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA | JAMA

Question What is the effect of ivermectin on duration of symptoms in adults with mild COVID-19? Network

Findings In this randomized clinical trial that included 476 patients, the duration of symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo (median time to resolution of symptoms, 10 vs 12 days; hazard ratio for resolution of symptoms, 1.07).

Meaning The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes.

https://jamanetwork.com/journals/jama/fullarticle/2777389?guestAccessKey=c866888b-46f8-41ab-a866-55beba52862a&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_term=mostread&utm_content=olf-widget_03082021